Currently out of the existing stock ratings of Rohin Patel, 5 are a BUY (83.33%), 1 are a HOLD (16.67%).
Analyst Rohin Patel, currently employed at JPMORGAN, has had 50% of price targets met with an average potential upside of 25.74%, reached in 211 days on average.
Rohin Patel has documented 11 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NPCE, Neuropace at 13-Nov-2026.
Analyst best performing recommendations are on HAE (HAEMONETICS).
The best stock recommendation documented was for HAE (HAEMONETICS) on 12/12/2025. The price target of $74 was fulfilled within 34 days with a profit of $9.49 (11.37%), with a performance score of 3.34.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 08-Nov-2017
$145
$24.84 (20.67%)
$140
16 days ago
(06-Nov-2026)
43/46 (93.48%)
$25.07 (20.90%)
393
Buy Since 10-Sep-2024
$142
$21.84 (18.18%)
$130
17 days ago
(05-Nov-2026)
12/14 (85.71%)
$17.89 (14.41%)
267
Buy Since 26-Nov-2013
$140
$19.84 (16.51%)
$90
1 months 13 days ago
(09-Oct-2026)
34/44 (77.27%)
$21.31 (17.95%)
444
Hold Since 06-Feb-2026
$123
$2.84 (2.36%)
$92
2 months 5 days ago
(17-Sep-2026)
24/24 (100%)
$15.4 (14.31%)
142
Buy Since 16-Aug-2021
$125
$4.84 (4.03%)
$90
2 months 19 days ago
(03-Sep-2026)
12/12 (100%)
$22.15 (21.54%)
372
Which stock is Rohin Patel most bullish on?
What Year was the first public recommendation made by Rohin Patel?